Dr. Postow Discusses Combination Therapy for Melanoma

Michael A. Postow, MD
Published: Tuesday, Dec 05, 2017



Michael A. Postow, MD, medical oncologist, Memorial Sloan Kettering Cancer Center, discusses combination therapy for patients with melanoma.

There are many new combination therapies for patients with melanoma, says Postow. In the BRAF-mutant population, there are combinations of BRAF and MEK inhibitors with immunotherapy drugs that are moving into phase III trials.

Immunotherapy combinations are also moving forward in clinical trials as well, adds Postow. Namely, combinations of IDO blockers and PD-1 agents.
 
SELECTED
LANGUAGE


Michael A. Postow, MD, medical oncologist, Memorial Sloan Kettering Cancer Center, discusses combination therapy for patients with melanoma.

There are many new combination therapies for patients with melanoma, says Postow. In the BRAF-mutant population, there are combinations of BRAF and MEK inhibitors with immunotherapy drugs that are moving into phase III trials.

Immunotherapy combinations are also moving forward in clinical trials as well, adds Postow. Namely, combinations of IDO blockers and PD-1 agents.
 



View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Advances in™ Melanoma: Exploring BRAF/MEK in Adjuvant and Neoadjuvant SettingsSep 28, 20191.5
Medical Crossfire®: What Does Data Tell Us About How to Optimize Checkpoint Inhibitor Strategies Across Lines of Care for Patients with Melanoma?Nov 30, 20191.5
Publication Bottom Border
Border Publication
x